Abzena Acquires TCRS for ADCs
By

Abzena, a Cambridge, UK-based life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has acquired The Chemistry Research Solution LLC (TCRS), a contract chemistry and bioconjugation business focused on antibody drug conjugates (ADCs).

With the acquisition, Abzena now has four principal holdings: Antitope, which provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunized therapeutic proteins, and cell line development for manufacture; PacificGMP, which provides contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies; PolyTherics, which pecializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals; and now TCRS is a contract chemistry and bioconjugation business focused on ADCs and which is establishing the capability to manufacture ADCs to GMP standards.

Source: Abzena

Leave a Reply

Your email address will not be published. Required fields are marked *